We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
TLX.AU

Price
26.19
Stock movement down
-0.39 (-1.47%)
Company name
Telix Pharmaceuticals Ltd
Exchange
(AU
,
Currency
AUD
)
Sector
Healthcare >
Biotechnology
Market cap
8.77B
Ent value
8.99B
Price/Sales
12.68
Price/Book
21.70
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
519.00
Forward P/E
84.48
PEG
-
EPS growth
-
1 year return
105.73%
3 year return
77.67%
5 year return
88.18%
10 year return
-
Last updated: 2025-04-12

DIVIDENDS

TLX.AU does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E519.00
Price to OCF152.48
Price to FCF265.63
Price to EBITDA118.17
EV to EBITDA121.18

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales12.68
Price to Book21.70
EV to Sales13.00

FINANCIALS

Per share

Per share data
Current share count334.72M
EPS (TTM)0.05
FCF per share (TTM)0.09

Income statement

Income statement data
Revenue (TTM)691.51M
Gross profit (TTM)438.67M
Operating income (TTM)65.27M
Net income (TTM)16.89M
EPS (TTM)0.05
EPS (1y forward)0.31

Margins

Margins data
Gross margin (TTM)63.44%
Operating margin (TTM)9.44%
Profit margin (TTM)2.44%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash118.84M
Net receivables97.27M
Total current assets255.26M
Goodwill117.75M
Intangible assets0.00
Property, plant and equipment0.00
Total assets745.96M
Accounts payable22.30M
Short/Current long term debt22.14M
Total current liabilities258.37M
Total liabilities341.98M
Shareholder's equity403.97M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)57.49M
Capital expenditures (TTM)24.49M
Free cash flow (TTM)33.00M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity4.18%
Return on Assets2.26%
Return on Invested Capital4.14%
Cash Return on Invested Capital8.09%

STOCK INFORMATION

Stock chart

Stock price data
Open25.70
Daily high26.72
Daily low25.67
Daily Volume1.25M
All-time high31.14
1y analyst estimate25.62
Beta2.38
EPS (TTM)0.05
Dividend per share-
Ex-div date-
Next earnings date22 May 2025

Downside potential

Downside potential data
TLX.AUS&P500
Current price drop from All-time high-15.90%-12.89%
Highest price drop-59.05%-56.47%
Date of highest drop12 May 20229 Mar 2009
Avg drop from high-16.42%-11.07%
Avg time to new high13 days12 days
Max time to new high315 days1805 days
COMPANY DETAILS
TLX.AU (Telix Pharmaceuticals Ltd) company logo
Marketcap
8.77B
Marketcap category
Mid-cap
Description
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Employees
0
Website
https://telixpharma.com
Investor relations
-
SEC filings
TLX.AU SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved